Table 1.
Overview of systemic treatments for metastatic cutaneous melanoma [18]
| Cochrane review | Relative effect (95% CI) | No. of patients (studies) | Quality evidence (grade) |
|---|---|---|---|
| Anti-PD-1 compared with chemotherapy | |||
| Overall survival | HR 0.42 (0.37–0.48) | 418 (1) | High |
| Progression-free survival | HR 0.49 (0.39–0.61) | 957 (2) | Moderate |
| Tumour response | RR 3.42 (2.38–4.92) | 1367 (3) | High |
| Toxicity (≥ G3) | RR 0.55 (0.31–0.97) | 1360 (9) | Low |
| Anti-PD-1 compared with anti-CTLA-4 | |||
| Overall survival | HR 0.63 (0.60–0.66) | 764 (1) | High |
| Progression-free survival | HR 0.54 (0.50–0.60) | 1465 (2) | High |
| Tumour response | RR 2.47 (2.01–3.04) | 1465 (2) | High |
| Toxicity (≥ G3) | RR 0.70 (0.54–0.91) | 1465 (2) | Low |
| Anti-CTLA-4 + chemotherapy compared with chemotherapy | |||
| Overall survival | HR 0.81 (0.65–1.01) | 1157 (2) | Low |
| Progression-free survival | HR 0.76 (0.69–0.92) | 502 (1) | Moderate |
| Tumour response | RR 1.28 (0.92–1.77) | 1157 (2) | Moderate |
| Toxicity (≥ G3) | RR 1.69 (1.19–2.42) | 1142 (2) | Moderate |
| Anti-CTLA-4 + anti-PD-1 compared with anti-CTLA-4 (overall survival not measured) | |||
| Progression-free survival | HR 0.40 (0.35–0.46) | 738 (2) | High |
| Tumour response | RR 3.50 (2.07–5.92) | 738 (2) | High |
| Toxicity (≥ G3) | RR 1.57 (0.85–2.92) | 764 (2) | Low |
CI confidence interval, CTLA-4 cytotoxic T-lymphocyte antigen-4, G3 grade 3, HR hazard ratio, PD-1 programmed cell death-1, RR relative risk